Many physicians have specialized in hyaluronic acid therapy and have obtained outstandings results. Your physician will want to discuss the details of treatment with you beforehand and answer any questions you may have.

Your physician has discovered that you have arthritis - degeneration of the joint cartilage. He has therefore recommended hyaluronic acid treatment with Biovisc Ortho. Biovisc Ortho is a viscoelastic solution for the treatment of the knee and other synovial joints.

How does BIOVISC-ORTHO work?
When physicians inject highly-pure synthetic hyaluronic acid into the affected joint, the quality of the joint fluid improves. This lubrication reduces pain and increases joint mobility.

In a treatment with Biovisc Ortho your doctor will recommend 3-5 injections per week depending on the seriousness of the arthritis. Over the course of treatment and after the third injection at the latest, you should notice a pain relief and increased mobility. The positive effect of hyaluronic acid treatment has been demonstrated by numerous scientific studies.

Symptoms improve significantly in three out of four patients. The benefits of treatment can last for several months after a cycle of injections. If necessary, Biovisc Ortho therapy can be repeated several times.

Excellent tolerance
Biovisc Ortho is distinguished by its excellent tolerance and is free of preservatives. In general, the injections are not painful. After treatment, may occur at the injection site and occasionally temporary pain may be experienced, heat and swelling.

BIOVISC ORTHO   SEE MANUFATURER     ORDER  
  • Sodium Hyaluronate 1.0%. Sterile viscoelastic solution for intra-articular injection

BIOVISC ORTHO is a sterile, transparent, homogeneous viscoelastic gel of Hyaluronic Acid. BIOVISC ORTHO contains 10 mg/ml of hyaluronic acid in buffered phosphate saline solution. BIOVISC ORTHO is formulated with injectable grade hyaluronic acid of biofermentation origin. BIOVISC ORTHO is a hyaluronic acid viscosupplement for treating mild to moderate osteoarthritis by providing joint lubrication. BIOVISC ORTHO is indicated to relief pain and stiffness of the knee joint in patients with mild to moderate osteoarthritis. Biovisc Ortho must not be administered to patients who are known to be hypersensitive to one of the constituents. Biovisc Ortho should not be used in infected or severely inflamed joints or in patients having skin diseases or infections in the area of the injection site. Biovisc Ortho is to be used only by qualified medical practitioner. Safety and effectiveness of injection in conjunction with other treatments have not been established. Remove any joint effusion before injection. Biovisc Ortho has not been tested on pregnant women and children less than 18 years. The physician should be aware of potential risks associated with the injection of biological substances. Transient pain or swelling of the injected joint may occur after intraarticular injection with Biovisc Ortho. Do not inject Biovisc Ortho outside the articulation, in synovialtissues and/or in the joint capsule, as such an injection might lead to undesirable local and regional inflammatory reactions. Do not inject Biovisc Ortho at intra-vascular region. Biovisc Ortho should not be administered through a needle previously used with medical solutions containing Benzalkonium chloride. Do not use disinfectants for skin preparation that contain quaternary Ammonium salts. Following the injection of Biovisc Ortho, patients may experience local symptoms in the joint being treated (pain, heat, redness and swelling). The use of an oral analgesic or anti-inflammatory drug during the first days of the treatment may be helpful for the patient. No information on the incompatibility of Biovisc Ortho with other solutions for intraarticular use is available to date. The Synovial joint, particularly the large weight-bearing joint, contains Hyaluronic acid, which has lubricating and shock-absorbing properties, allowing the joints to move normally and painlessly. In patients with degenerative joints disorders, such as osteoarthritis, the viscoelasticity of the Synovial fluid is markedly reduced, with a decrease of the lubricating and shock-absorbing functions. This results in a mechanical loading of the joint and the degeneration of the joint cartilage (restricted and painful joint movement). The administration of highly purified Hyaluronic acid can improve the viscoelastic properties of the Synovial joint. The lubricating and shock-absorbing properties of reduces pain and improves mobility of joint.

ADMINISTRATION Remove the ready-to-use syringe from the sterile container, gently twist off the tip cap of the Luer lock adapter, attach a needle and twist it gently until firmly in place. Biovisc Ortho is intended for injection into the Synovial cavity. Each pre-filled syringe is intended for single use only. The syringe should be used immediately after the individual syringe blister is opened. Use aseptic technique when handling the syringe and administering the injection. If the patient presents with effusion, the effusion should be removed before Biovisc Ortho is injected into the joint. Inject the entire contents of the syringe into one joint only. Discard any unused Biovisc Ortho. If treatment is being administered to different joints, use a separate syringe for each joint with separate needle.

Specification:

BIOVISC ORTHO 20mg/2ml
Utilisation :Sterile Hyaluronic Acid viscoelastic gel for intra-articular injection
Composition : Hyaluronic Acid 10 mg/1ml, Phosphate buffer saline q. s. (pH-7.2)
Origin : biofermentation
Molecular Weight : 2,8 to 3,5 mio Da
Presentation: 1 x prefilled glass syringe 2ml/3ml in a steril pack
Dosage: 3 injections each six months.
Needle: 18G-25G
Shelf Life: 36 Months.
Storage: between 2C to 25C. Do not freeze it.
Treatment : to be injected in the knee joint by an authorized medical practitioner
Public price: CHF 39,80 incl. taxes

To order please contact the distributor

BIOVISC ORTHO M   SEE MANUFATURER     ORDER  
  • Sterile Hyaluronic Acid viscoelastic solution for intra-articular injection.

BIOVISC ORTHO M is a sterile, transparent, homogeneous viscoelastic gel of high molecular weight Hyaluronic Acid. BIOVISC ORTHO M contains 20 mg/ml of hyaluronic acid and 5 mg/ml Mannitol in buffered phosphate saline solution. Mannitol is a strong anti-oxidant, and efficient free radical scavenger. Free radicals, play an important role in the degradation of hyaluronic acid. In this, way, mannitol stabilizes and slows down the degradation of hyaluronic acid and simultaneously increases theresidence of the viscosupplement BIOVISC ORTHO M in the joint. BIOVISC ORTHO M is formulated with injectable grade hyaluronic acid of biofermentation origin. BIOVISC ORTHO M is a hyaluronic acid viscosupplement for treating mild to moderate osteoarthritis by providing joint lubrication BIOVISC ORTHO M is indicated to relief pain and stiffness of the knee joint in patients with mild to moderate osteoarthritis. BIOVISC ORTHO M is intended for 3-injection treatment regimen use, i.e. three injections given at weekly intervals each six months. BIOVISC ORTHO M can relieve pain and improve mobility for up to 6 months, provided that the patient is suffering from mild to moderate osteoarthritis of the knee joint. BIOVISC ORTHO M should not be injected if the patient is known to be sensitive (allergy) to hyaluronic acid. Do not inject BIOVISC ORTHO M in the knee joint of patients having a skin disease or infection in the area or near the injection site. Do not inject BIOVISC ORTHO M if the knee is infected or inflamed. Do not prepare the skin with disinfectants containing quaternary ammonium salts such as benzalkonium chloride which may induce precipitation of HA. Do not inject BIOVISC ORTHO M intra-vascularly, extra-articularly or into the synovial tissues capsule. The safety and efficacy of BIOVISC ORTHO M for conditions other than osteoarthritis of the knee have not been established clinically. The safety and efficacy of the use of BIOVISC ORTHO M concomitantly with other intra-articular injectabels have not been established. The safety and efficacy of BIOVISC ORTHO M in severely inflamed knee joints have not been established. BIOVISC ORTHO M should be used with caution when there is evidence of lymphatic or venous stasis in the joint to be injected. Strict aseptic administration technique must be followed. The contents of the syringe are sterile. BIOVISC ORTHO M is intended for single use. The contents of the syringe must be used immediately after its packaging is opened. Discard an unused BIOVISC ORTHO M. Unused syringes should not be re-sterilized. Do not use BIOVISC ORTHO M if package is opened or damaged. Information for Patient Provide patients with a copy of the Patient Labeling prior to use. Mild to moderate pain, swelling and/or effusion of the injected knee have been reported in clinical trials that were related to intra-articular injection of BIOVISC ORTHO M. These events were typically transient and usually resolved on their own or with conservative treatment. As with any invasive joint procedure, it is recommended that the patient avoid strenuous activities (for example, high-impact sports such as soccer, tennis or jogging) or prolonged weight-bearing activities for approximately 48 hours following the intraarticular injection. The patient should consult his or her physician regarding the appropriate time to resume such activities. Age: Patient age should not be less than 18 years. Pregnancy: The safety and effectiveness of BIOVISC ORTHO M have not been established in pregnant women. Nursing mothers: It is not known if BIOVISC ORTHO M is excreted in human milk. The safety and effectiveness of BIOVISC ORTHO M have not been established in lactating women. Pediatrics: The safety and effectiveness of BIOVISC ORTHO M have not been established in pediatric patients. No specific adverse events reported through use of BIOVISC ORTHO M. However, common adverse reactions related to invasive procedures may be caused during the usage including following; Transient joint swelling, Pain, Heat, Redness, etc. BIOVISC ORTHO M is supplied in a 2mL/3mL, single use glass syringe with a Luer-lock fitting, packed in a blister pack. The contents of the syringe, stabilized non-animal hyaluronic acid gel, are sterile. It is recommended to use a needle (18G-25G) with adequate length to inject the gel into the joint knee. SHELF LIFE 24 Months. BIOVISC ORTHO M must be used prior to the expiry date printed on the package. Store BIOVISC ORTHO M between 2C to 25C. Do not freeze it. BIOVISC ORTHO M is a medical device designed to be injected in the knee joint by an authorized medical practitioner in accordance with the local applicable regulations.

Specification:

BIOVISC ORTHO M 40mg/2ml
Utilisation :Sterile Hyaluronic Acid + Mannitol for intra-articular injection.
Composition : Hyaluronic Acid 20 mg/1ml, Mannitol 5 mg/1ml, Phosphate buffer saline q. s. (pH-7.2)
Origin : biofermentation
Molecular Weight : 2,8 to 3,5 mio Da
Osmolarity : 375 mOsm/kg
Presentation: 1 x prefilled glass syringe 2ml/3ml in a steril pack
Dosage: 1-3 injections at weekly intervals each six months.
Needle: 18G-25G
Shelf Life: 24 Months.
Storage: between 2C to 25C. Do not freeze it.
Treatment : to be injected in the knee joint by an authorized medical practitioner
Public price: CHF 103,45 incl, taxes + logo of the medical device and others on the package (ce 0434, sterile, i temp. etc..)

BIOVISC ORTHO SINGLE   SEE MANUFATURER     ORDER  
  • Sterile Hyaluronic Acid viscoelastic solution for intra-articular injection.

BIOVISC ORTHO SINGLE is a sterile, transparent, homogeneous iscoelastic gel of cross linked Hyaluronic Acid. BIOVISC ORTHO SINGLE contains 30 mg/ml of cross linked hyaluronic acid in buffered phosphate saline solution. BIOVISC ORTHO SINGLE is formulated with injectable grade hyaluronic acid of biofermentation origin. BIOVISC ORTHO SINGLE is a hyaluronic acid viscosupplement for treating mild to moderate osteoarthritis by providing joint lubrication. BIOVISC ORTHO SINGLE is indicated to relief pain and stiffness of the knee joint in patients with mild to moderate osteoarthritis. BIOVISC ORTHO SINGLE is intended for single injection treatment use, i.e. to be administered once each six months. BIOVISC ORTHO SINGLE can relieve pain and improve mobility for up to 6 months, provided that the patient is suffering from mild to moderate osteoarthritis of the knee joint. BIOVISC ORTHO SINGLE should not be injected if the patient is known to be sensitive (allergy) to hyaluronic acid. Do not inject BIOVISC ORTHO SINGLE in the knee joint of patients having a skin disease or infection in the area or near the injection site. Do not inject BIOVISC ORTHO SINGLE if the knee is infected or inflamed. Do not prepare the skin with disinfectants containing quaternary ammonium salts such as benzalkonium chloride which may induce precipitation of HA. Do not inject BIOVISC ORTHO SINGLE intra-vascularly, extraarticularly or into the synovial tissues capsule. The safety and efficacy of BIOVISC ORTHO SINGLE for conditions other than osteoarthritis of the knee have not been established clinically. The safety and efficacy of the use of BIOVISC ORTHO SINGLE concomitantly with other intra-articular injectabels have not been established. The safety and efficacy of BIOVISC ORTHO SINGLE in severely inflamed knee joints have not been established. BIOVISC ORTHO SINGLE should be used with caution when there is evidence of lymphatic or venous stasis in the joint to be injected. Strict aseptic administration technique must be followed. The contents of the syringe are sterile. BIOVISC ORTHO SINGLE is intended for single use. The contents of the syringe must be used immediately after its packaging is opened. Discard an unused BIOVISC ORTHO SINGLE. Unused syringes should not be re-sterilized. Do not use BIOVISC ORTHO SINGLE if package is opened or damaged. Information for Patient: Provide patients with a copy of the Patient Labeling prior to use. Mild to moderate pain, swelling and/or effusion of the injected knee have been reported in clinical trials that were related to intra-articular injection of BIOVISC ORTHO SINGLE. These events were typically transient and usually resolved on their own or with conservative treatment. As with any invasive joint procedure, it is recommended that the patient avoid strenuous activities (for example, high-impact sports such as soccer, tennis or jogging) or prolonged weight-bearing activities for approximately 48 hours following the intraarticular injection. The patient should consult his or her physician regarding the appropriate time to resume such activities. Age: Patient age should not be less than 18 years. Pregnancy: The safety and effectiveness of BIOVISC ORTHO SINGLE have not been established in pregnant women. Nursing mothers: It is not known if BIOVISC ORTHO SINGLE is excreted in human milk. The safety and effectiveness of BIOVISC ORTHO SINGLE have not been established in lactating women. Pediatrics: The safety and effectiveness of BIOVISC ORTHO SINGLE have not been established in pediatric patients. No specific adverse events reported through use of BIOVISC ORTHO SINGLE. However, common adverse reactions related to invasive procedures may be caused during the usage including following;Transient joint swelling, Pain, Heat, Redness, etc. BIOVISC ORTHO SINGLE is supplied in 2mL/3mL, single use glass syringe with a Luer-lock fitting, packed in a blister pack. The contents of the syringe, stabilized non-animal hyaluronic acid gel, are sterile. It is recommended to use a needle (18G-25G) with adequate length to inject the gel into the joint knee. SHELF LIFE 24 Months. BIOVISC ORTHO SINGLE must be used prior to the expiry date printed on the package. Store BIOVISC ORTHO SINGLE between 2C to 25C. Do not freeze it. BIOVISC ORTHO SINGLE is a medical device designed to be injected in the knee joint by an authorized medical practitioner in accordance with the local applicable regulations.

Specification:

BIOVISC ORTHO Single 90mg/3ml
Utilisation :Sterile cross-linked Hyaluronic Acid viscoelastic gel for single intra-articular injection
Composition : Hyaluronic Acid 30 mg/1ml, Phosphate buffer saline q. s. (pH-7.2)
Origin : biofermentation
Molecular Weight : 2,8 to 3,5 mio Da
Osmolarity : 360 m0sm/kg
Presentation: 1 x prefilled glass syringe 2ml/3ml in a steril pack
Dosage: 1 single injection each six months.
Needle: 18G-25G
Shelf Life: 24 Months.
Storage: between 2C to 25C. Do not freeze it.
Treatment : to be injected in the knee joint by an authorized medical practitioner
Public price: CHF 169,80 incl. taxes

BIOVISC ORTHO PLUS   SEE MANUFATURER     ORDER  
  • Sterile Hyaluronic Acid viscoelastic solution for intra-articular injection.

BIOVISC ORTHO PLUS is a sterile, transparent, homogeneous viscoelastic gel of high molecular weight Hyaluronic Acid. BIOVISC ORTHO PLUS contains 20 mg/ml of hyaluronic acid in buffered phosphate saline solution. BIOVISC ORTHO PLUS is formulated with injectable grade hyaluronic acid of biofermentation origin. BIOVISC ORTHO PLUS is a hyaluronic acid viscosupplement for treating mild to moderate osteoarthritis by providing joint lubrication. BIOVISC ORTHO PLUS is indicated to relief pain and stiffness of the knee joint in patients with mild to moderate osteoarthritis. BIOVISC ORTHO PLUS is intended for 3-injection treatment regimen use, i.e. three injections given at weekly intervals each six months. BIOVISC ORTHO PLUS can relieve pain and improve mobility for up to 6 months, provided that the patient is suffering from mild to moderate osteoarthritis of the knee joint. BIOVISC ORTHO PLUS should not be injected if the patient is known to be sensitive (allergy) to hyaluronic acid. Do not inject BIOVISC ORTHO PLUS in the knee joint of patients having a skin disease or infection in the area or near the injection site. Do not inject BIOVISC ORTHO PLUS if the knee is infected or inflamed. Do not prepare the skin with disinfectants containing quaternary ammonium salts such as benzalkonium chloride which may induce precipitation of HA. Do not inject BIOVISC ORTHO PLUS intra-vascularly, extra-articularly or into the synovial tissues capsule. The safety and efficacy of BIOVISC ORTHO PLUS for conditions other than osteoarthritis of the knee have not been established clinically. The safety and efficacy of the use of BIOVISC ORTHO PLUS concomitantly with other intra-articular injectabels have not been established. The safety and efficacy of BIOVISC ORTHO PLUS in severely inflamed knee joints have not been established. BIOVISC ORTHO PLUS should be used with caution when there is evidence of lymphatic or venous stasis in the joint to be injected. Strict aseptic administration technique must be followed. The contents of the syringe are sterile. BIOVISC ORTHO PLUS is intended for single use. The contents of the syringe must be used immediately after its packaging is opened. Discard an unused BIOVISC ORTHO PLUS. Unused syringes should not be re-sterilized. Do not use BIOVISC ORTHO PLUS if package is opened or damaged. Information for Patient: Provide patients with a copy of the Patient Labeling prior to use. Mild to moderate pain, swelling and/or effusion of the injected knee have been reported in clinical trials that were related to intra-articular injection of BIOVISC ORTHO PLUS. These events were typically transient and usually resolved on their own or with conservative treatment. As with any invasive joint procedure, it is recommended that the patient avoid strenuous activities (for example, high-impact sports such as soccer, tennis or jogging) or prolonged weight-bearing activities for approximately 48 hours following the intraarticular injection. The patient should consult his or her physician regarding the appropriate time to resume such activities. Age: Patient age should not be less than 18 years. Pregnancy: The safety and effectiveness of BIOVISC ORTHO PLUS have not been established in pregnant women. Nursing mothers: It is not known if BIOVISC ORTHO PLUS is excreted in human milk. The safety and effectiveness of BIOVISC ORTHO PLUS have not been established in lactating women. Pediatrics: The safety and effectiveness of BIOVISC ORTHO PLUS have not been established in pediatric patients. No specific adverse events reported through use of BIOVISC ORTHO PLUS. However, common adverse reactions related to invasive procedures may be caused during the usage including following;Transient joint swelling, Pain, Heat, Redness, etc. BIOVISC ORTHO PLUS is supplied in a 1mL/2mL/3mL, single use glass syringe with a Luer-lock fitting, packed in a blister pack. The contents of the syringe, stabilized non-animal hyaluronic acid gel, are sterile. It is recommended to use a needle (18G-25G) with adequate length to inject the gel into the joint knee. SHELF LIFE 36 Months. BIOVISC ORTHO PLUS must be used prior to the expiry date printed on the package. Store BIOVISC ORTHO PLUS between 2C to 25C. Do not freeze it. BIOVISC ORTHO PLUS is a medical device designed to be injected in the knee joint by an authorized medical practitioner in accordance with the local applicable regulations.

Specification:

BIOVISC ORTHO Plus 40mg/2ml
Utilisation :Sterile Hyaluronic Acid for intra-articular injection.
Composition : Hyaluronic Acid 20 mg/1ml, Phosphate buffer saline q. s. (pH-7.2)
Origin : biofermentation
Molecular Weight : 2,8 to 3,5 mio Da
Osmolarity :354 mOsm/kg
Presentation: 1 x prefilled glass syringe 1 ml/2ml/3ml in a steril pack
Dosage: 1-3 injections at weekly intervals each six months.
Needle: 18G-25G
Shelf Life: 36 Months.
Storage: between 2C to 25C. Do not freeze it.
Treatment : to be injected in the knee joint by an authorized medical practitioner
Public price: CHF 99,35 incl, taxes